STOCK TITAN

Kymera Therapeutics Provides Webcast Information for December 14 Investor Event

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Kymera Therapeutics (NASDAQ: KYMR) announced a virtual investor event scheduled for December 14, 2022, where they will share clinical updates on their Phase 1 trial of the IRAK4 degrader KT-474. This trial targets patients with hidradenitis suppurativa or atopic dermatitis. Additionally, the company will discuss its oncology pipeline developments. Kymera focuses on targeted protein degradation to develop innovative therapies for various diseases, leveraging its proprietary Pegasus platform.

Positive
  • Scheduled investor event to update on clinical trial progress.
  • Focus on innovative targeted therapies addressing untapped disease pathways.
Negative
  • None.

Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline

WATERTOWN, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today shared webcast information for the virtual investor event that the Company will host on December 14, 2022, from 8:00-9:30 AM ET. The Company’s management team will provide a clinical update on Part C of the Phase 1 clinical trial evaluating its IRAK4 degrader KT-474 in patients with either hidradenitis suppurativa or atopic dermatitis, as well as an update on its oncology pipeline.

To join the webcast, please visit this link, or the “Events & Presentations” page of the Investors section on the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event.

About Kymera Therapeutics
Kymera Therapeutics (Nasdaq: KYMR) is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera’s Pegasus platform is a powerful drug discovery engine, advancing novel small molecule therapies that harness the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. With a focus on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutics designed to address the most intractable pathways and provide new treatments for patients. Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. For more information, visit www.kymeratx.com.

Founded in 2016, Kymera is headquartered in Watertown, Mass. Kymera has been named a “Fierce 15” biotechnology company by Fierce Biotech and has been recognized by the Boston Business Journal as one of Boston’s “Best Places to Work.” For more information about our people, science, and pipeline, please visit www.kymeratx.com or follow us on Twitter or LinkedIn.

Investor Contact:
Bruce Jacobs
Chief Financial Officer
investors@kymeratx.com
857-285-5300

Chris Brinzey
Managing Director, Westwicke
chris.brinzey@westwicke.com
339-970-2843

Media Contact:
Todd Cooper
Senior Vice President, Corporate Affairs
media@kymeratx.com
857-285-5300


FAQ

What is the focus of Kymera Therapeutics' clinical research with KT-474?

Kymera Therapeutics is focusing on the IRAK4 degrader KT-474 for treating hidradenitis suppurativa and atopic dermatitis.

When is Kymera Therapeutics' investor event scheduled?

The investor event is scheduled for December 14, 2022, from 8:00-9:30 AM ET.

What will Kymera discuss during their upcoming investor event?

Kymera will provide updates on their Phase 1 clinical trial of KT-474 and their oncology pipeline.

How is Kymera Therapeutics innovating in drug development?

Kymera is pioneering targeted protein degradation to develop new therapies for challenging diseases.

What is the significance of the Pegasus platform for Kymera Therapeutics?

The Pegasus platform helps Kymera advance novel small molecule therapies by utilizing the body's protein recycling mechanisms.

Kymera Therapeutics, Inc.

NASDAQ:KYMR

KYMR Rankings

KYMR Latest News

KYMR Stock Data

2.54B
63.89M
1.27%
108.43%
14.09%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WATERTOWN